Cargando…

Cariprazine in Pediatric Patients with Autism Spectrum Disorder: Results of a Pharmacokinetic, Safety and Tolerability Study

OBJECTIVE: Cariprazine is a dopamine D(3)-preferring D(3)/D(2) and serotonin 5-HT(1A) receptor partial agonist approved to treat adults with schizophrenia and manic/mixed or depressive episodes associated with bipolar I disorder. This study, which is the first to evaluate cariprazine in pediatric pa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yeung, Paul P., Johnson, Kimball A., Riesenberg, Robert, Orejudos, Amelia, Riccobene, Todd, Kalluri, Hari V., Malik, Paul R., Varughese, Shane, Findling, Robert L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Mary Ann Liebert, Inc., publishers 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10458368/ https://www.ncbi.nlm.nih.gov/pubmed/37437109 http://dx.doi.org/10.1089/cap.2022.0097

Ejemplares similares

Cariprazine pharmacokinetics
Publicado: (2022)

Asenapine pharmacokinetics and tolerability in a pediatric population
por: Dogterom, Peter, et al.
Publicado: (2018)

Population Pharmacokinetics of Cariprazine and its Major Metabolites
por: Periclou, Antonia, et al.
Publicado: (2020)

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine
por: Kiss, Béla, et al.
Publicado: (2019)

Cariprazine alleviates core behavioral deficits in the prenatal valproic acid exposure model of autism spectrum disorder
por: Román, Viktor, et al.
Publicado: (2021)

Cariprazine hydrochloride for schizophrenia
Publicado: (2021)

Pharmacotherapy of emotional and behavioral symptoms associated with autism spectrum disorder in children and adolescents
por: Stepanova, Ekaterina, et al.
Publicado: (2017)

Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety
por: Laszlovszky, István, et al.
Publicado: (2021)

Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder
por: Vieta, Eduard, et al.
Publicado: (2019)

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial
por: Durgam, Suresh, et al.
Publicado: (2016)

Cariprazine: Patients with Treatment-Resistant Schizophrenia
por: Aubel, Thomas
Publicado: (2021)

Defining the therapeutic reference range for cariprazine
por: Kapás, M., et al.
Publicado: (2023)

Sleep, Growth, and Puberty After 2 Years of Prolonged-Release Melatonin in Children With Autism Spectrum Disorder
por: Malow, Beth A., et al.
Publicado: (2020)

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis
por: Nasrallah, Henry A., et al.
Publicado: (2017)

Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder
por: Maras, Athanasios, et al.
Publicado: (2018)

Update on schizophrenia and bipolar disorder: focus on cariprazine
por: Roberts, Rona Jeannie, et al.
Publicado: (2016)

Case Report: Long-Acting Oral Cariprazine
por: Dyrmishi, Emanuela, et al.
Publicado: (2022)

Cariprazine — an Alternative Treatment for Clozapine-resistant Schizophrenia?
por: Montgomery, Adam, et al.
Publicado: (2023)

Case series: Cariprazine in early-onset schizophrenia
por: Ivanova, Elena, et al.
Publicado: (2023)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies
por: Barabássy, Ágota, et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”
por: Periclou, Antonia, et al.
Publicado: (2019)

Review: The Autistic Brain: Thinking Across the Spectrum
por: Findling, Robert L.
Publicado: (2013)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies [Corrigendum]
Publicado: (2021)

Cariprazine Use in Early Psychosis: Three Case Reports
por: Coentre, Ricardo, et al.
Publicado: (2021)

Cariprazine on Psychosis: Beyond Schizophrenia – A Case Series
por: Bajouco, Miguel, et al.
Publicado: (2022)

Benzodiazepine use during cariprazine treatment in acute schizophrenia
por: Correll, C., et al.
Publicado: (2022)

Melatonin: From Pharmacokinetics to Clinical Use in Autism Spectrum Disorder
por: Lalanne, Sébastien, et al.
Publicado: (2021)

Pediatric Prolonged-Release Melatonin for Sleep in Children with Autism Spectrum Disorder: Impact on Child Behavior and Caregiver’s Quality of Life
por: Schroder, Carmen M., et al.
Publicado: (2019)

A Case Report of Treatment With Cariprazine in a Recurrent Psychosis Presumably Induced by Methamphetamine
por: Moran, Robert A, et al.
Publicado: (2023)

Cariprazine as a treatment across the bipolar I spectrum from depression to mania: mechanism of action and review of clinical data
por: Stahl, Stephen M., et al.
Publicado: (2020)

Binding kinetics of cariprazine and aripiprazole at the dopamine D(3) receptor
por: Frank, Annika, et al.
Publicado: (2018)

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data
por: Szatmári, Balázs, et al.
Publicado: (2020)

Improving Mood and Cognitive Symptoms in Huntington's Disease With Cariprazine Treatment
por: Molnar, Maria Judit, et al.
Publicado: (2022)

Cariprazine in the Treatment of Bipolar Disorder: Within and Beyond Clinical Trials
por: Do, André, et al.
Publicado: (2021)

Minimal Effects of Cariprazine on Prolactin Levels in Bipolar Disorder and Schizophrenia
por: Culpepper, Larry, et al.
Publicado: (2022)

Evaluation of the Effect of Cariprazine on Memory and Cognition in Experimental Rodent Models
por: Zlatanova, Hristina Ivanova, et al.
Publicado: (2022)

The improvement of motor symptoms in Huntington’s disease during cariprazine treatment
por: Csehi, Reka, et al.
Publicado: (2023)

Multiple dose pharmacokinetics of inhaled loxapine in subjects on chronic, stable antipsychotic regimens
por: Spyker, Daniel A., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_p7jppfslg5c0v47mf5otepp5sk